Rocket One's Hoth Therapeutics Reports Strong HT-001 Efficacy Results, Ends Phase 2a Early and Plans to Pursue Phase 3 to Bring Treatment to Cancer Patients
A potential Phase 3 trial depends on FDA feedback and completion of required development activities.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rocket One (RKTO) announced that subsidiary Hoth Therapeutics has decided to end its Phase 2a trial of HT-001 early. Hoth attributes the decision to interim efficacy findings it considers supportive of further development. HT-001 is an investigational topical aprepitant formulation for skin toxicities associated with epidermal growth factor receptor (EGFR) inhibitor cancer therapies.
Hoth plans to complete the remaining data review and seek FDA feedback on a potential Phase 3 program, including study design, efficacy endpoints, patient selection, statistical considerations, safety requirements and manufacturing readiness. The interim findings are preliminary and may change as additional data are collected and finalized. Starting Phase 3 depends on regulatory feedback and completion of required development activities.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointHoth considers interim HT-001 efficacy findings supportive of ending Phase 2a early and pursuing further development.
- Minor point. Forward-looking: it has not happened yet and may not happen.Hoth plans to seek FDA feedback on a potential Phase 3 program for HT-001.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Interim results are preliminary and may change as additional data are collected and finalized.
- Minor point. Forward-looking: it has not happened yet and may not happen.Phase 3 initiation depends on regulatory feedback and completion of required development activities.
Details
Market Reaction – RKTO
On Nov 3, the day this news came out, the latest delayed price for RKTO is 1.00% above the previous close. Argus tracked a peak move of +11.9% during the session. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $0.45. Relative volume is exceptionally heavy at 136.5x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Terms
interim analysis medical
efficacy endpoints medical
neurokinin-1 receptor antagonist medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive interim findings drive early trial conclusion; Hoth prepares to seek FDA alignment on a potential pivotal study for cancer treatment–related skin toxicity
HT-001 is an investigational topical formulation of aprepitant being developed to treat dermatologic toxicities associated with epidermal growth factor receptor (EGFR) inhibitor cancer therapies. These skin complications can cause significant discomfort, affect patients' quality of life, and lead to interruptions or modifications of cancer treatment.
Following review of the available interim efficacy and safety data, Hoth determined that the findings support concluding Phase 2a early and pursuing regulatory discussions on the next stage of development.
"We are encouraged by the strength of the interim findings and believe they support taking the next step toward a potential Phase 3 program," said Robb Knie, Chief Executive Officer of Rocket One. "Our goal is to help patients manage the skin toxicity associated with EGFR inhibitor therapy so they can better tolerate their cancer treatment. We are now focused on presenting the data to the FDA and establishing the requirements for the next stage of HT-001's development."
Interim Findings Support Decision to Conclude Phase 2a Early
Hoth's decision reflects its assessment of the clinical activity observed in the interim analysis and the information needed to guide further development.
The Company plans to complete the remaining data review and analysis necessary to support its regulatory submission and proposed development strategy. Interim results are preliminary and may change as additional data are collected and finalized.
Preparing for a Potential Phase 3 Program
Hoth intends to request FDA feedback on the proposed pathway for HT-001, including the design of a potential pivotal study, selection of efficacy endpoints, patient population, statistical considerations, safety requirements, and manufacturing readiness.
Initiation of a Phase 3 trial will depend on regulatory feedback, completion of required development activities.
"Moving toward a potential pivotal program is a meaningful development objective for Hoth," Knie added. "We believe these findings warrant a focused discussion with the FDA about how to evaluate HT-001 in a larger study and generate the evidence needed to support a potential registration pathway."
Addressing Skin Toxicity During Cancer Treatment
EGFR inhibitors are used to treat several types of cancer. Their associated dermatologic toxicities, including rash and related symptoms, can create a substantial burden for patients and complicate treatment management.
HT-001 is designed to deliver aprepitant, a neurokinin-1 receptor antagonist, directly to affected skin. Its development program is evaluating whether this topical approach can provide clinically meaningful improvements in EGFR inhibitor–associated skin toxicity with an acceptable safety profile.
HT-001 remains investigational and has not been approved by the FDA for any indication.
About HT-001
HT-001 is an investigational topical formulation of aprepitant under development for dermatologic toxicities associated with EGFR inhibitor cancer therapies. Its clinical program is evaluating efficacy, safety, and tolerability in this oncology supportive-care setting.
About Hoth Therapeutics
Hoth Therapeutics, a biotechnology subsidiary of Rocket One, is advancing investigational therapeutic programs, including HT-001, with the goal of addressing unmet patient needs.
About Rocket One Inc.
Rocket One Inc. is a publicly traded technology company building a portfolio across artificial intelligence infrastructure, advanced semiconductor technologies, space and defense systems, and autonomous platforms. Rocket One is advancing licensed spintronic and nanomagnetic computing technologies for AI acceleration and radiation-tolerant computing, together with Swarm Stage AI, a drone-swarm threat-emulation and counter-UAS training platform. Tracer Drone Technologies, LLC (a Rocket One company) provides end-to-end drone solutions including hardware, software, FAA training, and technical support to help public safety, commercial, and enterprise organizations successfully deploy and maintain their aerial programs.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the Company's strategic repositioning, the development potential of the licensed technologies, the suitability of those technologies for orbital, defense, and other applications, anticipated future operations and market opportunities. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These forward-looking statements are based on the Company's current expectations and assumptions and are subject to numerous risks and uncertainties, including, without limitation: the early-stage nature of the licensed technologies, which have not been fabricated as integrated devices, validated in space environments, or qualified for any commercial or government program, and the absence of any commercial product; the substantial additional capital the Company will require to fabricate, test, and qualify the licensed technologies, including for radiation tolerance and space deployment; the long development timelines associated with novel semiconductor and materials platforms; competition from larger, better-funded and well recognized companies in the semiconductor, AI hardware, space, and defense computing sectors; the Company's ability to recruit qualified leadership and technical personnel in nanomagnetic devices, semiconductor engineering, and aerospace systems; the Company's ability to comply with diligence milestones under the Virginia Commonwealth University license agreements, the failure of which could result in loss of license rights; intellectual property risks; export control and government contracting risks associated with defense and space applications; and the risks inherent in a strategic pivot. Additional risk factors are described in the Company's filings with the Securities and Exchange Commission ("SEC") including the Company's most recent Annual Report on Form 10-K and the Company's other filings made with the SEC. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. The Company may not realize its expectations, and its beliefs may not prove correct. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as the Company's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance, or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact
LR Advisors LLC
Email: investorrelations@rocketone.space
Phone: (678) 570-6791
www.rocketone.space
View original content to download multimedia:https://www.prnewswire.com/news-releases/rocket-ones-hoth-therapeutics-reports-strong-ht-001-efficacy-results-ends-phase-2a-early-and-plans-to-pursue-phase-3-to-bring-treatment-to-cancer-patients-302927285.html
SOURCE Rocket One Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why is Rocket One's Hoth Therapeutics ending the HT-001 Phase 2a trial early?
Hoth determined that the interim efficacy findings support concluding Phase 2a early and pursuing regulatory discussions about further development. Its assessment followed review of available interim efficacy and safety data. The results remain preliminary and may change as additional data are collected and finalized.
What must happen before Hoth can start a Phase 3 trial of HT-001?
Starting a Phase 3 trial depends on regulatory feedback and completion of required development activities. Hoth intends to request FDA feedback on the proposed pathway, including study design, efficacy endpoints, patient population, statistical considerations, safety requirements and manufacturing readiness.